This aligns with PAK6’s documented role in chemoresistance pathways, where overexpression confers resistance to oxaliplatin in colorectal cancer and 5-FU in breast cancer (Bhowmick et al., 2023; Chen et al., 2015; Huang et al., 2022). Here, PAK6 is linked to breast cancer.